Drug Profile


Alternative Names: Depsipeptide; FK 228; FR 901228; Istodax; NSC 630176; NSC 630176D

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Celgene Corporation; Lymphoma Academic Research Organisation; University of Birmingham; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Depsipeptides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Multiple myeloma; T cell lymphoma; T-cell leukaemia
  • Phase I Haematological malignancies
  • Discontinued Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 03 Jul 2017 Registered for Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (IV)
  • 02 Jul 2017 Romidepsin receives Orphan Drug status for Peripheral T-cell lymphoma in Japan before July 2017
  • 13 Jun 2017 Columbia University plans a phase I/II trial for T-cell lymphoma (Combination therapy) in USA (NCT03161223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top